Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company,…
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously…
PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer
Basel, October 19, 2025 – Novartis today presents new Pluvictoâ„¢ (lutetium (177Lu)…